news
SARS-CoV-2 specific antibodies persist for five months in mild cases
In a study of mild-to-moderate COVID-19 patients scientists established that the level of certain antibodies remained stable for five months.
List view / Grid view
Antibodies
video
On-demand webinar: Complete workflow solution from gene-to-protein
23 October 2020 | By
Our full gene-to-protein workflow can support your research for rapid protein production early during drug development so you can minimize changes from R&D to bioproduction.
news
Study reveals roles of antibodies in SARS-CoV-2 disease severity
Researchers have found that the level of antibodies in the serum of SARS-CoV-2 patients correlated with disease severity.
news
SARS-CoV-2-targeting antibodies persist for at least three months in COVID-19 patients
Two separate studies show that IgG serotype antibodies targeting the SARS-CoV-2 spike protein are still detectable in patient’s blood and saliva after 90 days.
news
Researchers make steps towards a universal flu vaccine
A research team has developed a potentially universal flu vaccine that has demonstrated success in mice.
webinar
SARS-CoV-2 testing: automation of high-throughput qPCR and COVID-seq
8 October 2020 | By SPT Labtech
In this on-demand webinar, we explored the various methods of COVID-19 testing: qPCR, COVID-seq, antigen and antibody detection, and others. Coupling these assays with low volume, high speed automation has made great strides toward achieving the high-throughput testing essential to ending this pandemic.
news
Study reveals 10 SARS-CoV-2 epitopes that could be targeted by antibodies
An analysis of SARS-CoV-2 has allowed researchers to identify epitopes recognised by a large fraction of COVID-19 patients, with 10 that could be targeted by antibodies.
news
Antibodies from recovered COVID-19 patients inhibit SARS-CoV-2 infection in cells
Pre-clinical studies in cells and hamsters have shown that potent antibodies from COVID-19 patients can prevent infection from SARS-CoV-2.
news
Why do some patients develop COVID-19 pneumonia?
Scientists reveal that some patients who develop severe COVID-19 symptoms mount ineffective immune responses due to a lack of type I interferons, either through genetic mutation or inactivation by auto-reactive antibodies.
whitepaper
Webinar: Optimised workflow for rapid identification of neutralising antibodies against viral particles
Helping in the race to identify effective neutralising antibodies against the spike protein of SARS-CoV-2 virus as the COVID-19 global death rate continues to rise.
whitepaper
On-demand webinar: Exploring absorbance-based assay applications: From virus to cannabis research
Discover how absorbance detection works as well as different types of absorbance-based assay applications that scientists can utilise for their research.
whitepaper
Article: Imaging dataset for COVID-19 research
Molecular Devices helps Recursion produce the largest publicly available set of human cellular morphological data for COVID-19 therapeutic research.
news
Tiny antibody component could treat or prevent SARS-CoV-2
The component, now developed into a drug called Ab8, was highly effective at treating and preventing SARS-CoV-2 infection in animal models.
article
Expert view: Measuring protein interactions in blood – not as trivial as it sounds
In the continuing battle against COVID-19, researchers now must identify the best candidates for vaccines and convalescent serum therapies against the virus.
whitepaper
Application note: Accurate affinity profiling of a SARS-CoV-2 antibody in serum
In this application note, Fluidic Analytics show that by using MDS on the Fluidity One-W Serum we can accurately detect and characterise the binding affinity of antibodies to virus proteins directly in human serum.